As always, thank you CT. And please understand we never think you are ever being difficult. I think most of us here believe in Leronlimab so much that we do think placebo patients are being short changed. But of course the rest of the world would not see it that way and thus the protocols as designed are needed to establish that more concrete evidence.

Speaking of trial design, I think we really hurt ourselves with M/M. First the obvious error was using the standard flu symptoms scoring system for primary endpoint. Second, was 2:1. For S/C I wholeheartedly agree for ethical reasons, but for M/M where most patients get better on their own, we may have hurt ourselves in the statistical calculations by having the uneven ratio without the ethical benefit.